The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: A meta-analysis

Endocrine

Volumn 43, Issue 1, 2013, Pages 68-77

  Li, Dan ^a   Shao, Leping ^a   Zhou, Haiyan ^a   Jiang, Wei ^a   Zhang, Wei ^a   Xu, Yan ^a  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Cinacalcet; Dialysis; KDOQI; Secondary hyperparathyroidism

Indexed keywords

CALCIUM; CINACALCET; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; PLACEBO; VITAMIN D;

ARTICLE; BONE METABOLISM; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; HUMAN; HYPOCALCEMIA; HYPOTENSION; META ANALYSIS; MINERAL METABOLISM; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VOMITING;

EID: 84872322829     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-012-9711-2     Document Type: Article

References (45)

1. T. Shigematsu, T. Akizawa, E. Uchida, Y. Tsukamoto, M. Lwasaki, S. Koshikawa, Long-term cinacalcet HCl treatment improved bone metabolism in Japanese hemodialysis patients with secondary hyperparathyroidism. Am. J. Nephrol. 29, 230-236 (2009)
2. M. Chonchol, F. Locatelli, H.E. Abboud, C. Charytan, A.L.M. de Francisco, S. Jolly et al., A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am. J. Kidney Dis. 53(2), 197-207 (2009)
3. G.A. Block, P.S. Klassen, J.M. Lazarus, N. Ofsthun, E.G. Lowrie, G.M. Chertow, Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. 15, 2208-2218 (2004)
4. E.W. Young, J.M. Albert, S. Satayathum, D.A. Goodkin, R.L. Pisoni, T. Akiba et al., Predictors and consequences of altered mineral metabolism: the dialysis outcomes and practice patterns study. Kidney Int. 67, 1179-1187 (2005)
5. S.C. Verberckmoes, V. Persy, G.J. Behets, E. Neven, A. Hufkens, H. Zebger-Gong et al., Uremia-related vascular calcification: more than apatite deposition. Kidney Int. 71, 298-303 (2007)
6. G.M. Chertow, Z.J. Lu, X. Xu, T.G. Knight, W.G. Goodman, D.A. Bushinsky et al., Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols. Hemodial. Int. (2011). doi: 10.1111/j.1542-4758. 2011.00642.x
7. L. Lucchi, C. Carboni, L. Stipo, V. Malaguti, F. Ferrari, K. Graziani et al., Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience. Artif. Organs 35(12), 1186-1193 (2011)
8. P. Urena, S.H. Jacobson, E. Zitt, M. Vervloet, F. Malberti, N. Ashman et al., Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice- the ECHO observational study. Nephrol. Dial. Transplant. 24, 2852-2859 (2009)
9. National Kidney Foundation, K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 42(suppl 4), S1-S202 (2003)
10. M.D. Danese, V. Belozeroff, K. Smirnakis, K.J. Rothman, Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin. J. Am. Soc. Nephrol. 3, 1423-1429 (2008)
11. D. Fouque, H. Roth, G. London et al., Achieving K/DOQI targets for phosphorus and calcium metabolism by dialysis modality among prevalent ESRD patients in France in 2006. The French prospective phosphorus and calcium observatory in maintenance dialysis (abstract). J. Am. Soc. Nephrol. 18, 9 (2007)
12. A.J. Brown, Vitamin D analogs for secondary hyperparathyroidism: what does the future hold? J. Steroid Biochem. Mol. Biol. 103, 578-583 (2007)
13. W. Seeherunvong, O. Nwobi, C.L. Abitbol, J. Chandar, J. Strauss, G. Zilleruelo, Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patient. Pediatr. Nephrol. 21, 1434-1439 (2006)
14. L. Greenbaum, R. Grenda, P. Qiu, I. Restaino, A. Wojtak, A. Paredes et al., Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis. Pediatr. Nephrol. 20, 622-630 (2005)
15. E. Zitt, C. Jager, A.R. Rosenkranz, M. Eigner, K. Kodras, J. Kovarik et al., Effective use of cinacalcet for the treatment of secondary hyperparathyroidism in Austrian dialysis patients-results of the Austrian cohort of the ECHO study. Wien. Klin. Wochenschr. 123, 45-52 (2011)
16. E.F. Nemeth, M.E. Steffey, L.G. Hammerland, B.C.P. Hung, B.C. VanWagenen, E.G. DelMar et al., Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc. Natl Acad. Sci. U S A 95, 4040-4045 (1998)
17. Nobuo. Nagano, Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Pharmacol. Ther. 109, 339-365 (2006)
18. J. Cunningham, M. Danese, K. Olson, P. Classen, G.M. Chertow, Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 68, 1793-1800 (2005)
19. M. Ketteler, K.J. Martin, M. Cozzolino, D. Goldsmith, A. Sharma, S. Khan et al., Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study and baseline characteristics of the IMPACT SHPT study. Nephrol. Dial. Transplant. 0, 1-8 (2011)
20. Kidney Disease: Improving Global Outcomes, KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. Suppl 76(Suppl 113), S1-S130 (2009)
21. K. Uhlig, J.S. Berns, B. Kestenbaum, R. Kumar, M.B. Leonard, K.J. Martin et al., KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, and treatment of CKD-mineral and bone disorder (CKD-MBD). Am. J. Kidney Dis. 55, 773-799 (2010)
22. S.M. Moe, G.M. Chertow, J.W. Coburn, L.D. Quarles, W.G. Goodman, G.A. Block et al., Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int. 67, 760-771 (2005)
23. J.S. Lindberg, B. Culleton, G. Wong, M.F. Borah et al., Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J. Am. Soc. Nephrol. 16, 800-807 (2005)
24. J.R. Sterrett, J. Strom, H.K. Stummovoll, U. Bahner, A. Disney, S.D. Soroka et al., Cinacalcet HCl (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. Clin. Nephrol. 68(1), 10-17 (2007)
25. P. Messa, F. Macário, M. Yaqoob, K. Bouman, J. Braun, B. Albertini et al., The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin. J. Am. Soc. Nephrol. 3, 36-45 (2008)
26. S. Fishbane, W.B. Shapiro, D.B. Corry, S.L. Vicks, M. Roppolo, K. Rappaport et al., Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyrodism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin. J. Am. Soc. Nephrol. 3, 1718-1725 (2008)
27. E.M. El-Shafey, A.E. Alsahow, K. Alsaran, A.A. Sabry, M. Atia, Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients. Ther. Apher. Dial. 15(6), 547-555 (2011)
28. H. Ogata, M. Mizobuchi, F. Koiwa, E. Kinugasa, T. Akizawa, Clinical significance of parathyroid intervention on CKD-MBD management. Nephrol. Dial. Transplant. 1(suppl 3), 9-13 (2008)
29. G.B. Spasovski, Bone health and vascular calcification relationships in chronic kidney diaease. Int. Urol. Nephrol. 39, 1209-1216 (2007)
30. G. Conzo, A. Perna, N. Avenia, R.M. De Santo, C.D. Pietra, A. Palazzo et al., Evaluation of the 'putative' role of intraoperative intact parathyroid hormone assay during parathyroidectomy for secondary hyperparathyroidism. A retrospective study on 35 consecutive patients. Endocrine (2012). doi: 10.1007/s12020-012-9648-5
31. S. Moe, T. Drueke, J. Cunningham, W. Goodman, K. Martin, K. Olgaard et al., Definition, evaluation, and classification of renal osteodystrophy: a position statemen from kidney disease: improving global outcomes (KDIGO). Kidney Int. 69, 1945-1953 (2006)
32. G. Jean, C. Chazot, B. Charra, 12 months cinacalcet therapy in hemodialysis patients with secondary hyperparathyroidism: effect on bone markers. Clin. Nephrol. 68(1), 63-64 (2007)
33. S.J. Steddon, S.L.S. Fan, J. Cuuningham, New prospects for the management of renal bone disease. Nephron Clin. Prac. 99, 1-7 (2005)
34. Y.H.H. Lien, A.L. Silva, D. Whittman, Effect of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrol. Dial. Transplant. 20, 1232-1237 (2005)
35. A. Yajima, T. Akizama, Y. Tsukamoto, S. Kurihara, A. Ito, K Study Group: impact of cinacalcet hydrochloride on bone histology in patients with secondary hyperparathyroidism. Ther. Apher. Dial. 12(suppl 1), S38-S43 (2008)
36. J. Muscheites, M. Wigger, E. Drueckler, D.C. Fischer, G. Kundt, D. Haffner, Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease. Pediatr. Nephrol. 23, 1823-1829 (2008)
37. H. Komaba, S. Nakanishi, A. Fujimori, M. Tanaka, J. Shin, K. Shibuya et al., Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment Gland Size in Patients with Secondary Hyperparathyroidism. Clin. J. Am. Soc. Nephrol. 5, 2305-2314 (2010)
38. L.H. Duntas, N. Stathatos, Cinacalcet as alternative treatment for primary hyperparathyroidism: achievements and prospects. Endocrine 39, 199-204 (2011)
39. N. Nagano, Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Pharmacol. Ther. 109(3), 339-365 (2006)
40. M. Peacock, M.A. Bolognese, M. Brofsky, S. Scumpia, L.R. Sterling, S. Cheng et al., Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J. Clin. Endocrinol. Metab. 94(12), 4860-4867 (2009)
41. M. Peacock, J.P. Bilezikian, M.A. Bolonese, M. Brofsky, S. Scumpia, L.R. Sterling et al., Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. J. Clin. Endocrinol. Metab. 96(1), E9-E18 (2011)
42. J.F. Raposo, A. Pires, H. Yokota, H.G. Ferreira, A mathematical model of calcium and phosphorus metabolism in two forms of hyperparathyroidism. Endocrine 41, 309-319 (2012)
43. M. Eandi, L. Pradelli, S. Iannazzo, S. Chiroli, G. Pontoriero, Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy. Pharmaconomics 28(11), 1041-1054 (2010)
44. R. Garside, M. Pitt, R. Anderson, S. Mealing, R.D. Souza, K. Sein, The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective. Nephrol. Dial. Transplant. 22, 1428-1436 (2007)
45. R. Boer, A.M. Lalla, V. Belozeroff, Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United States. J. Med. Econ. (2012). doi: 10.3111/13696998.2012.664799